The direct systemic low-dose insulin infusion was enough to increase CCNE2 gene expression and stimulate IUGR myoblasts toward the S/G2/M cell cycle stages without reducing pancreatic β-cell mass. The gene discussed is INS; the disease is fetal growth restriction.